Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus

Cardiovascular Revascularization Medicine

Volumn 10, Issue 1, 2009, Pages 5-11

  Nishio, Kazuaki ^a   Shigemitsu, Meiei ^a   Kodama, Yusuke ^a   Konno, Noburu ^a   Katagiri, Takashi ^a   Kobayashi, Youichi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bare metal stent; Major adverse cardiac events; Pioglitazone; Restenosis; Sirolimus eluting stent

Indexed keywords

INSULIN; PIOGLITAZONE; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BARE METAL STENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ELUTING STENT; EDEMA; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEART DISEASE; HUMAN; INSULIN RESISTANCE; LABORATORY TEST; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SIDE EFFECT;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES MELLITUS, TYPE 2; DRUG-ELUTING STENTS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; METALS; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; SIROLIMUS; STENTS; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149513938     PISSN: 15538389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.carrev.2008.06.004     Document Type: Article

References (40)

1. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents (part I & part II). Circulation 2003;107:2274-2279, 2383-2389.
2. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R., and for the RAVEL Study Group. A randomized comparison of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. Hill R.A., Dundar Y., Bakhai A., Dickson R., and Wally T. Drug-eluting stents: an early systemic review to inform policy. Eur Heart J 25 (2004) 902-919
4. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
5. Katritsis D.G., Karvouni E., and loannidis J.P. Meta-analysis comparing drug-eluting stents with bare metal stents. Am J Cardiol 95 (2005) 640-643
6. Nordmann A.J., Briel M., and Bucher H.C. Mortality in randomized controlled trials comparing drug-eluting stents in coronary artery disease: a meta-analysis. Eur Heart J 27 (2006) 2784-2814
7. Hoffmann R., and Mintz G.S. Coronary in-stent restenosis-predictors, treatment and prevention restenosis. Eur Heart J 21 (2000) 1739-1749
8. Takagi T., Yamamuro A., Tomita K., Yamabe K., Katayama M., Morioka S., Akasaka T., and Yoshida K. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89 (2002) 318-322
9. Marx N., Wohrle J., Nusser T., Walcher D., Rinker A., Hombach V., Koenig W., and Hoher M. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 112 (2005) 2792-2798
10. Nishio K., Sakurai M., Kusuyama T., Shigemitsu M., Fukui T., Kawamura K., Itoh S., Konno N., and Katagiri T. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in type 2 diabetes. Diabetes Care 29 (2006) 101-106
11. Riche D.M., Valderrama R., and Henyan N.N. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention. Diabetes Care 30 (2007) 384-388
12. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J., and PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
13. Nishio K., Fukui T., Tsunoda F., Kawamura K., Itoh S., Konno N., Ozawa K., and Katagiri T. Insulin resistance as an independent risk factor for restenosis after coronary stenting. Intern J Cardiol 103 (2005) 128-134
14. Alberti K.G.M.M., Zimmet P., and for the WHO consultation. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus-provisional report of a WHO consultation. Diabetic Med 15 (1998) 539-553
15. Anon. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 21 (2000) 1502-1513
16. Anon. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-969
17. Tenerz A., Norhammar A., Silveira A., Hamsten A., Nilsson G., Ryden L., and Malmberg K. Diabetes, insulin resistance, and metabolic syndrome in patients with acute myocardial infarction without previously known diabetes. Diabetes Care 26 (2003) 2770-2776
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28 (1985) 412-419
19. Friedwald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1978) 499-502
20. Schwartz R.S., Chronos N.A., and Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 44 (2004) 1373-1385
21. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., Suddath W.O., Weissman N.J., Torguson R., Kent K.M., Pichard A.D., Satler L.F., Waksman R., and Serruys P.W. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1466-1467
22. Spaulding C., Henry P., Teiger E., Beatt K., Bramucci E., Carrie D., Slama M.S., Merkely B., Erglis A., Margheri M., Varenne O., Cebrian A., Stoll H.P., Snead D.B., Bode C., and TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355 (2006) 1093-1104
23. Elezi S., Kastrati A., Pache J., Wehinger A., Hadamitzky M., Dirschinger J., Neumann F.J., and Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32 (1998) 1866-1873
24. Betriu A., Masotti M., Serra A., Alonso J., Fernandez-Aviles F., Gimeno F., Colman T., Zueco J., Delcan J.L., Garcia E., and Calabuig J. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 34 (1999) 1498-1506
25. Mudra H., di Marco C., de Jaegere P., Figulla H.R., Macaya C., Zahn R., Wennerblom B., Rutsch W., Voudris V., Regar E., Henneke K.H., Schachinger V., and Zeiher A. A randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study). Circulation 104 (2001) 1343-1349
26. Martinez-Elbal L., Ruiz-Nodar J.M., Zueco J., Lopez-Minguez J.R., Moreu J., Calvo I., Ramirez J.A., Alonso M., Vazquez N., Lezaun R., and Rodriguez C. Direct coronary stenting versus stenting with balloon predilation: the DISCO trial: Direct Stenting of COronary Arteries. Eur Heart J 23 (2002) 633-640
27. Gilbert J., Raboud J., and Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Care 27 (2004) 990-994
28. Scheen A.J., and Warzée F. Diabetes is still a risk factor for restenosis after drug-eluting stent in coronary arteries. Diabetes Care 27 (2004) 1840-1841
29. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L., and SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
30. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
31. Eisenstein E.L., Anstrom K.J., Kong D.F., Shaw L.K., Tuttle R.H., Mark D.B., Kramer J.M., Harrington R.A., Matchar D.B., Kandzari D.E., Peterson E.D., Schulman K.A., and Califf R.M. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297 (2006) 159-168
32. Miyazaki Y., Mahankali A., and Matsuda M. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24 (2001) 710-719
33. Goetze S., Xi X.P., and Kawano H. PPAR gamma-ligands inhibits migration mediated by multiple chemoattractants in vascular smooth muscle cells. J Cardiovascular Pharmacol 33 (1999) 798-806
34. Igarashi M., Hirata A., and Yamaguchi H. Characterization of an inhibitory effect of pioglitazone in balloon-injured vascular smooth muscle cell growth. Metabolism 50 (2001) 955-962
35. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., Usui M., Kitamoto S., Ichiki T., and Takeshita A. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40 (2002) 687-693
36. Nishio K., Shigemitsu M., Kusuyama T., Fukui T., Kawamura K., Itoh S., Konno N., and Katagiri T. Insulin resistance in nondiabetic patients with acute myocardial infarction. Cardiovasc Revasc Med 7 (2006) 54-60
37. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., Dormandy J., and PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
38. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M., and PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with Type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49 (2007) 1772-1780
39. Schömig A., Kastrati A., and Wessely R. Prevention of restenosis by systemic drug therapy back to future?. Circulation 112 (2005) 2759-2761
40. Hoffmann R., Mintz G.S., and Mehran R. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol 31 (1998) 43-49